Decoding the efficacy and safety profiles of anti-hypertensive agents by targeting RAAS: A systematic review and meta-analysis of clinical trials DOI

Starry H. Rampengan,

Derren David Christian Homenta Rampengan, Roy Novri Ramadhan

et al.

Electronic Journal of General Medicine, Journal Year: 2025, Volume and Issue: 22(3), P. em645 - em645

Published: April 1, 2025

<b>Introduction: </b>This study reviews the efficacy and safety of angiotensin receptor neprilysin inhibitor (ARNI), nonsteroidal mineralocorticoid antagonists (NMRA), brain rennin-angiotensin system (RAS) therapy, ribonucleic acid (RNA)-based therapy with evaluating systolic blood pressure diastolic control as well by counting adverse events.<br /> <b>Methods: </b>Risk Bias 2.0 were used for quality appraisal RevMan 5.4 was applied meta-analysis.<br <b>Results:</b> From five databases, 20 articles selected review. Six high-risk fourteen low-risk studies. ARNI RNA-based therapies improved BP regulation, while NMRA RAS less effective in managing high pressure. In terms safety, had fewer events, whereas more AEs compared to their groups.<br <b>Conclusion:</b> outperforms four antihypertensive drugs studied underscoring its potential leading option justifying further research.

Language: Английский

Decoding the efficacy and safety profiles of anti-hypertensive agents by targeting RAAS: A systematic review and meta-analysis of clinical trials DOI

Starry H. Rampengan,

Derren David Christian Homenta Rampengan, Roy Novri Ramadhan

et al.

Electronic Journal of General Medicine, Journal Year: 2025, Volume and Issue: 22(3), P. em645 - em645

Published: April 1, 2025

<b>Introduction: </b>This study reviews the efficacy and safety of angiotensin receptor neprilysin inhibitor (ARNI), nonsteroidal mineralocorticoid antagonists (NMRA), brain rennin-angiotensin system (RAS) therapy, ribonucleic acid (RNA)-based therapy with evaluating systolic blood pressure diastolic control as well by counting adverse events.<br /> <b>Methods: </b>Risk Bias 2.0 were used for quality appraisal RevMan 5.4 was applied meta-analysis.<br <b>Results:</b> From five databases, 20 articles selected review. Six high-risk fourteen low-risk studies. ARNI RNA-based therapies improved BP regulation, while NMRA RAS less effective in managing high pressure. In terms safety, had fewer events, whereas more AEs compared to their groups.<br <b>Conclusion:</b> outperforms four antihypertensive drugs studied underscoring its potential leading option justifying further research.

Language: Английский

Citations

0